SCHEMBL29969263

SCHEMBL29969263

COc1ccc(S(=O)(=O)Nc2cc(Br)cnc2OCCCN(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 10/20 0.48
CACNA1H O95180 8/20 0.48
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CCR9 P51686 1/20 0.45
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
PIK3CA P42336 2/20 0.43
MTOR P42345 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21513746 1.00 CACNA1B (0.48) CACNA1BCACNA1HHTTLMNATSHR
SCHEMBL29968192 0.89 ALDH1A1 (0.48) CACNA1BCACNA1HHTTSMN1; SMN2ALDH1A1
SCHEMBL21513762 0.89 ALDH1A1 (0.48) CACNA1BCACNA1HHTTSMN1; SMN2ALDH1A1
SCHEMBL21512855 0.89 KEAP1 (0.47) CACNA1BCACNA1HHDAC3HDAC4HDAC1
SCHEMBL29968164 0.89 KEAP1 (0.47) CACNA1BCACNA1HHDAC3HDAC4HDAC1
SCHEMBL21512853 0.88 CACNA1B (0.55) CACNA1BCACNA1HPIK3CAMTORALDH1A1
SCHEMBL29968351 0.88 CACNA1B (0.55) CACNA1BCACNA1HPIK3CAMTORALDH1A1
SCHEMBL29970032 0.88 CACNA1B (0.51) CACNA1BCACNA1HTSHRSMN1; SMN2PIK3CA
SCHEMBL21512860 0.88 CACNA1B (0.48) CACNA1BCACNA1HHTTCCR9HDAC3
SCHEMBL21512858 0.88 CACNA1B (0.46) CACNA1BCACNA1HHTTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187742-B2 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy XRAD THERAPEUTICS, INC. (US) 2025-01-07 US disclosed
EP-4327877-A2 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRad Therapeutics, Inc. (US) 2024-02-28 EP disclosed
EP-3784671-B1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRAD THERAPEUTICS INC (US) 2023-10-11 EP disclosed
US-20220315606-A1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRAD HOLDING CAYMAN LIMITED (KY) 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315606-A1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY ATM, CHEK2, CHEK1 CACNA1B 4878/4885CACNA1H 4862/4885HTT 2506/4885
US-12187742-B2 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy ATM, CHEK2, CHEK1 CACNA1B 4878/4885CACNA1H 4862/4885HTT 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.